|
Index | - | P/E | - | EPS (ttm) | -0.96 | Insider Own | - | Shs Outstand | 67.30M | Perf Week | 22.83% |
Market Cap | 221.43M | Forward P/E | - | EPS next Y | -1.10 | Insider Trans | - | Shs Float | 8.77M | Perf Month | 67.82% |
Income | -62.60M | PEG | - | EPS next Q | -0.21 | Inst Own | 51.10% | Short Float | 6.95% | Perf Quarter | -9.84% |
Sales | 0.37M | P/S | 605.01 | EPS this Y | -36.70% | Inst Trans | 4.86% | Short Ratio | 2.81 | Perf Half Y | -69.95% |
Book/sh | 4.33 | P/B | 0.78 | EPS next Y | -55.60% | ROA | -21.70% | Target Price | 24.25 | Perf Year | -74.49% |
Cash/sh | 4.42 | P/C | 0.77 | EPS next 5Y | - | ROE | -30.10% | 52W Range | 1.68 - 19.74 | Perf YTD | -43.87% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -82.83% | Beta | - |
Dividend % | - | Quick Ratio | 14.70 | Sales past 5Y | - | Gross Margin | - | 52W Low | 101.79% | ATR | 0.31 |
Employees | 202 | Current Ratio | 14.70 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 68.64 | Volatility | 12.70% 12.49% |
Optionable | No | Debt/Eq | 0.06 | EPS Q/Q | 27.90% | Profit Margin | - | Rel Volume | 0.13 | Prev Close | 3.51 |
Shortable | Yes | LT Debt/Eq | 0.03 | Earnings | May 16 BMO | Payout | - | Avg Volume | 216.70K | Price | 3.39 |
Recom | 1.70 | SMA20 | 30.66% | SMA50 | 40.64% | SMA200 | -51.72% | Volume | 27,892 | Change | -3.42% |
![]() |
|
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise; and GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase I clinical trial for the treatment of r/r B-ALL. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite